Maryalice Stetler-Stevenson, M.D., Ph.D.
Maryalice  Stetler-Stevenson, M.D., Ph.D.
Staff Clinician
Head, Flow Cytometry Unit

Flow Cytometric Evaluation of Biomarkers The Flow Cytometry Laboratory is a clinical laboratory that provides state of the art diagnostic clinical flow cytometric immunophenotyping of hematolymphoid neoplasia for National Institutes of Health (NIH) patients and essential support for NCI clinical protocols. Specimens are submitted for primary diagnosis, sub-classification, staging, to detect therapeutic targets (e.g. antibody based therapy), prognostication, to evaluate changing signs or symptoms (e.g. new onset of neurological symptoms in patient with lymphoma), and to follow response to therapy under protocol dictated schedules (NCI patients only). The majority of flow cytometric testing performed by the Flow Cytometry Laboratory involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. The Laboratory also provides specialized unique protocol mandated tests that are not available from commercial laboratories and develops new tests as required to support NCI clinical protocols.

Areas of Expertise
flow cytometry

Contact Info

Maryalice Stetler-Stevenson, M.D., Ph.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 2N108
Bethesda, MD 20892
301-402-1424
stetler@mail.nih.gov

Flow Cytometric Evaluation of Biomarkers The Flow Cytometry Laboratory is a clinical laboratory that provides state of the art diagnostic clinical flow cytometric immunophenotyping of hematolymphoid neoplasia for National Institutes of Health (NIH) patients and essential support for NCI clinical protocols. Specimens are submitted for primary diagnosis, sub-classification, staging, to detect therapeutic targets (e.g. antibody based therapy), prognostication, to evaluate changing signs or symptoms (e.g. new onset of neurological symptoms in patient with lymphoma), and to follow response to therapy under protocol dictated schedules (NCI patients only). The majority of flow cytometric testing performed by the Flow Cytometry Laboratory involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. The Laboratory also provides specialized unique protocol mandated tests that are not available from commercial laboratories and develops new tests as required to support NCI clinical protocols.

Selected Publications
  1. Korde N, Carlsten M, Lee M, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.
    Haematologica. [Epub ahead of print], 2014. [ Journal Article ]
  2. Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho J, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.
    Haematologica. [Epub ahead of print], 2014. [ Journal Article ]
  3. Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M.
    Leuk. Res.. 38: 371-6, 2014. [ Journal Article ]
  4. Roschewski M, Stetler-Stevenson M, Yuan C, Mailankody S, Korde N, Landgren O.
    J. Clin. Oncol.. 32: 475-6, 2014. [ Journal Article ]
  5. Stetler-Stevenson M.
    Blood. 123: 1281-2, 2014. [ Journal Article ]

Dr. Stetler-Stevenson received her Ph.D. and M.D. from Northwestern University Medical School, Chicago, where she also trained in anatomic pathology. She completed a fellowship in hematopathology in the Laboratory of Pathology, NCI, before becoming Chief of the Flow Cytometry Unit. Dr. Stetler-Stevenson's interests include the study of factors active in lymphomagenesis and progression in lymphoid neoplasia as well as advancing the state of the art in the field of clinical flow cytometry.

Name Position
Gregory Jasper Medical Technologist
Catharine McCoy Medical Technologist
Dalia Salem Ph. D. Postdoctoral Fellow (Visiting)
Linda Weaver Medical Technologist
Constance M. Yuan, M.D., Ph.D. Staff Clinician

Research

Flow Cytometric Evaluation of Biomarkers The Flow Cytometry Laboratory is a clinical laboratory that provides state of the art diagnostic clinical flow cytometric immunophenotyping of hematolymphoid neoplasia for National Institutes of Health (NIH) patients and essential support for NCI clinical protocols. Specimens are submitted for primary diagnosis, sub-classification, staging, to detect therapeutic targets (e.g. antibody based therapy), prognostication, to evaluate changing signs or symptoms (e.g. new onset of neurological symptoms in patient with lymphoma), and to follow response to therapy under protocol dictated schedules (NCI patients only). The majority of flow cytometric testing performed by the Flow Cytometry Laboratory involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated by various clinical protocols. The Laboratory also provides specialized unique protocol mandated tests that are not available from commercial laboratories and develops new tests as required to support NCI clinical protocols.

Publications

Selected Publications
  1. Korde N, Carlsten M, Lee M, Minter A, Tan E, Kwok M, Manasanch E, Bhutani M, Tageja N, Roschewski M, Zingone A, Costello R, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Trepel J, Childs R, Landgren O.
    Haematologica. [Epub ahead of print], 2014. [ Journal Article ]
  2. Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho J, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A.
    Haematologica. [Epub ahead of print], 2014. [ Journal Article ]
  3. Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, Tageja N, Maric I, Mulquin M, Roschewski M, Kwok M, Liewehr D, Landgren O, Stetler-Stevenson M.
    Leuk. Res.. 38: 371-6, 2014. [ Journal Article ]
  4. Roschewski M, Stetler-Stevenson M, Yuan C, Mailankody S, Korde N, Landgren O.
    J. Clin. Oncol.. 32: 475-6, 2014. [ Journal Article ]
  5. Stetler-Stevenson M.
    Blood. 123: 1281-2, 2014. [ Journal Article ]

Biography

Dr. Stetler-Stevenson received her Ph.D. and M.D. from Northwestern University Medical School, Chicago, where she also trained in anatomic pathology. She completed a fellowship in hematopathology in the Laboratory of Pathology, NCI, before becoming Chief of the Flow Cytometry Unit. Dr. Stetler-Stevenson's interests include the study of factors active in lymphomagenesis and progression in lymphoid neoplasia as well as advancing the state of the art in the field of clinical flow cytometry.

Team

Name Position
Gregory Jasper Medical Technologist
Catharine McCoy Medical Technologist
Dalia Salem Ph. D. Postdoctoral Fellow (Visiting)
Linda Weaver Medical Technologist
Constance M. Yuan, M.D., Ph.D. Staff Clinician